Summary
Adinazolam is a short-acting triazolobenzodiazepine originally investigated as both an anxiolytic and antidepressant but never FDA approved. In clinical trials (10-90 mg/day) it showed rapid relief of anxiety and modest antidepressant efficacy comparable to tricyclics with fewer anticholinergic effects. Human studies found adinazolam causes the most mental and physical sedation compared to diazepam and lorazepam, along with significant mental unpleasantness. Recreationally it produces a calm effect with less amnesia than diazepam, though individual reports vary. Because of its short half-life, interdose rebound anxiety is common and redosing drives escalation.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 5-15mg | 15-30mg | 30-50mg | 50mg+ |
| Sublingual | 5-15mg | 15-30mg | 30-50mg | 50mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|
| Oral | 10-25 min | 1-2 hrs | 1.5-3 hrs | 4-16 hrs | 120-0 min |
| Sublingual | 10-25 min | 1-2 hrs | 1.5-3 hrs | 4-16 hrs | 120-0 min |
Tolerance
Build-up
develops over 1–4 weeks of daily use; hypnotic tolerance faster than anxiolytic tolerance
Reset
weeks to months depending on half-life and duration of use; taper recommended
Effects
Positive
- Muscle Relaxation
- Physical Euphoria
- Muscle relaxation
- Anxiolytic
- Physical euphoria
Negative
- Respiratory Depression
- Motor impairment
- Respiratory depression
- Sedation
- Sedative
Positive
- Anxiety Suppression
- Anxiety suppression
Negative
- Cognitive Impairment
- Motor Control Loss
- Memory Suppression
- Thought Deceleration
- Motor control loss
- Amnesia
- Thought deceleration
- Dizziness
Positive
- Increased libido
- Appetite enhancement
Negative
- Disinhibition
- Acuity suppression
- Double vision
- Decreased Libido
- Acuity Suppression
- Visual acuity suppression
- Dulled perception
- Perception of bodily heaviness